Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gremlin-2, DAN family BMP antagonist (GREM2) is a secreted glycoprotein belonging to the DAN domain family characterized by a cysteine knot motif and antagonist activity toward bone morphogenetic proteins (BMPs), especially BMP2 and BMP4[3][1]. By directly binding BMPs, GREM2 inhibits BMP-mediated signaling, influencing critical processes including embryonic morphogenesis, skeletal development, tooth formation, adipose tissue regulation, and cardiac development and repair[2][3]. Structurally, GREM2 forms homo- and heterodimers, and exerts its biological effects by physically preventing BMPs from activating their cellular receptors, modulating pathways essential for normal patterning and organogenesis. Dysregulation of GREM2 expression or function has been linked to disorders such as selective tooth agenesis, aberrant bone formation, and cardiovascular pathologies[2][3].
Antagonism of BMP2, BMP4, and related BMPs via direct binding; Inhibition of BMP-driven Smad/Runx2 signaling; Modulation of noncanonical BMP pathways (e.g., JNK activation in cardiac tissue)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gremlin-2, DAN family BMP antagonist (GREM2).